Aerocrine, Inc. partnered with JFK Communications for the US launch of NIOX MINO, a device that monitors exhaled nitric oxide (eNO), a marker of airway inflammation. eNO is a state-of-the-art method for monitoring asthma patients, and Aerocrine is a global leader in developing and marketing technologies that accurately measure eNO.
JFK Communications provided a comprehensive content-driven communications strategy that included
A national media relations campaign targeting 170+ media outlets
Development of collateral materials including launch press materials, a revised US NIOX MINO product brochure and a brochure to communicate the medical utility of eNO
Creation of NIOX MINO Web content, including product and reimbursement information
Posting NIOX MINO video content to social media websites including YouTube
Advocacy relations to build relationships with key asthma groups
Congress support for the NIOX MINO launch at the American Thoracic Society (ATS) annual meeting
The launch of NIOX MINO was extensively covered by top tier newspapers, general medical and respiratory trade publications, online health media, and broadcast media, earning more than 62,000,000 media impressions.
JFK Communications was also instrumental in establishing an ongoing working relationship with Allergy and Asthma Network Mothers of Asthmatics (AANMA), a leading patient advocacy group providing information, education and support to asthma patients and caregivers.
The US launch of NIOX MINO is an example of JFK Communications' extensive experience providing public relations support to medical technology companies.